Are Professional Sports Teams Buying the Right HBOT Chambers?

Hyperbaric oxygen therapy has moved from the margins of elite sport to something close to standard practice. Walk into the training facility of a top-tier professional sports team today and you are more likely than not to find a hyperbaric chamber somewhere on the premises. The NFL, the NBA, the Premier League, the top rugby competitions, and the major combat sports organisations have all seen significant adoption over the past decade.

The names associated with HBOT in professional sport are well known. LeBron James has spoken publicly about owning a hard-shell chamber and using it as a central pillar of his recovery. Several NFL franchises, including the Dallas Cowboys, the New England Patriots, and the Seattle Seahawks, have been publicly associated with hyperbaric programmes. In European football, clubs including Manchester City and Chelsea have invested in clinical-grade hyperbaric infrastructure. The All Blacks have used HBOT as part of their recovery protocols for years. In combat sports, the adoption rate among elite fighters is exceptionally high, and the UFC's ownership has made no secret of its enthusiasm for the technology.

The question that rarely gets asked in the coverage of all this activity is a simple one: are these teams buying the right chambers?

What Teams Are Actually Buying

To answer that question, it helps to understand what the market for professional sports HBOT procurement actually looks like.

The majority of chambers purchased by professional sports teams are soft-shell units. These are portable, inflatable chambers that operate at pressures between 1.3 and 1.5 ATA and deliver air or mild oxygen enrichment rather than pure oxygen at clinical concentrations. They require no permanent installation, no physician oversight in most jurisdictions, no ASME PVHO certification, and no specialised operator training. They can be ordered, delivered, and operational within days. They cost a fraction of a clinical hard-shell unit.

Hard-shell chambers, by contrast, operate at pressures of 2.0 ATA and above. They deliver 100% oxygen under pressure, which is the mechanism that drives the physiological effects documented in the clinical literature. They require permanent installation, structural assessment of the space they occupy, compliance with ASME PVHO-1 for design and fabrication and PVHO-2 for ongoing in-service maintenance, trained operators, and in most jurisdictions some form of medical oversight. They are significantly more expensive to procure, install, and maintain.

The procurement pattern in professional sport reflects these differences almost perfectly. Soft-shell chambers are ubiquitous. Hard-shell chambers are the exception.

Estimates based on publicly available information and industry sources suggest that somewhere between 60 and 80 percent of the hyperbaric chambers owned by professional sports teams across the major leagues and competitions are soft-shell units operating at or below 1.5 ATA. The figure varies by sport and by league, but the direction is consistent.

Why This Matters: The Pressure Problem

The clinical evidence for hyperbaric oxygen therapy is almost entirely built on studies conducted at pressures of 2.0 ATA and above, using 100% oxygen.

This is not a minor technical detail. Pressure is the mechanism. The therapeutic effect of HBOT depends on dissolving oxygen directly into blood plasma at concentrations that cannot be achieved at normal atmospheric pressure. The amount of oxygen dissolved in plasma increases in proportion to the partial pressure of oxygen, which is a function of both the total pressure in the chamber and the concentration of oxygen being breathed. At 1.3 ATA breathing air, the increase in dissolved plasma oxygen is modest. At 2.0 ATA breathing 100% oxygen, it is substantial.

The studies that have demonstrated HBOT's effects on inflammation modulation, tissue repair, angiogenesis, neurological recovery, and wound healing were conducted at clinical pressures. When researchers at the Sagol Center for Hyperbaric Medicine and Research published their landmark work on post-concussion syndrome and traumatic brain injury, they used 60 sessions at 1.5 ATA with 100% oxygen, and in subsequent protocols, 2.0 ATA. When the Israeli Defence Forces research on PTSD and neurological injury was conducted, it used clinical pressures. The evidence base that has made HBOT credible as a serious medical intervention was not built on 1.3 ATA soft-shell chambers.

This creates a significant gap between what professional sports teams are buying and what the evidence supports.

The Concussion Problem Is Particularly Acute

Nowhere is this gap more consequential than in the management of concussion and repetitive head trauma.

Professional contact sport has a concussion problem that is well documented and not yet solved. American football, rugby union, rugby league, ice hockey, and combat sports all involve repeated subconcussive and concussive impacts over careers that can span a decade or more. The neurological consequences, ranging from persistent post-concussion syndrome to the longer-term patterns associated with chronic traumatic encephalopathy, represent one of the most serious medical challenges in professional sport.

HBOT has emerged as one of the most mechanistically coherent interventions available for the neurological consequences of head trauma. The mechanism is straightforward: the injured brain is in a state of metabolic crisis, with elevated oxygen demand and compromised delivery. Hyperbaric oxygen addresses this directly by dramatically increasing the oxygen available to compromised neural tissue, supporting the metabolic processes required for repair and reducing the neuroinflammation that compounds the initial injury.

But the evidence for these neurological effects is at clinical pressures. A soft-shell chamber at 1.3 ATA does not produce the plasma oxygen concentrations required to drive the neurological mechanisms that the research has documented. Teams that are managing concussed athletes with soft-shell chambers are not delivering the intervention that the evidence supports. They are delivering something that feels like HBOT, that is marketed as HBOT, and that may produce some benefit through mild oxygen enrichment and the relaxation response of lying in a pressurised environment, but that is not the same intervention.

Why Teams Buy Soft-Shell Chambers Anyway

Understanding why professional sports teams default to soft-shell procurement requires understanding the incentive structure they are operating within.

The primary driver is convenience. Soft-shell chambers require no structural modification to a training facility, no regulatory engagement, no medical oversight infrastructure, and no specialised staffing. A team can acquire one, install it in a recovery room, and have athletes using it the same week. The procurement decision can be made by a performance director or a head of medical services without involving architects, engineers, regulatory consultants, or hospital-grade clinical governance.

The secondary driver is cost. A clinical hard-shell monoplace chamber costs substantially more than a soft-shell unit, and that gap widens further when installation, compliance, and ongoing maintenance are factored in. For a professional sports team with a large training facility budget, the absolute cost difference is not prohibitive, but the complexity cost often is.

The third driver is marketing. The soft-shell chamber market has been extremely effective at positioning its products as equivalent to clinical HBOT for recovery purposes. The language used in product marketing, and often repeated by the athletes and teams who use these products, does not always distinguish clearly between mild hyperbaric and clinical hyperbaric. Teams that have invested in soft-shell chambers have a natural incentive to describe them in terms that justify the investment.

There is also a regulatory dimension. In many jurisdictions, operating a hard-shell chamber at clinical pressures requires medical oversight and triggers regulatory obligations that soft-shell chambers at lower pressures do not. Teams that want to offer HBOT as a recovery tool without building the clinical governance infrastructure to support it find soft-shell chambers a more straightforward path.

What the Right Procurement Looks Like

This is not an argument that soft-shell chambers have no place in professional sport. For general recovery, sleep quality, and the management of minor soft tissue injuries, mild hyperbaric may offer some benefit, and the low risk profile of these devices means the cost-benefit calculation is reasonable even if the evidence is limited.

But for the clinical applications that matter most in professional sport, particularly concussion management, traumatic brain injury recovery, and the management of serious musculoskeletal injuries, the evidence points clearly toward clinical-grade hard-shell chambers operating at 2.0 ATA and above with 100% oxygen delivery.

Teams that are serious about using HBOT as a clinical tool, rather than as a recovery room amenity, need to think about procurement differently. That means:

Matching the chamber to the clinical need. If the goal is general recovery and wellness, a soft-shell chamber may be appropriate. If the goal is managing concussion, supporting neurological recovery, or treating serious injury, a clinical hard-shell chamber is the appropriate tool. These are different devices serving different purposes, and treating them as interchangeable is a procurement error.

Building the clinical infrastructure to support hard-shell use. A clinical chamber requires trained operators, a medical oversight structure, and compliance with the relevant standards, including ASME PVHO-1 for the chamber itself and PVHO-2 for its ongoing maintenance and inspection. Teams that invest in hard-shell chambers without investing in the supporting infrastructure are not getting the benefit they are paying for.

Separating procurement from marketing. The soft-shell chamber market is commercially sophisticated and the product positioning is compelling. Teams making procurement decisions should be evaluating chambers against the clinical evidence, not against marketing materials. The question to ask is not whether a chamber is described as hyperbaric, but what pressure it operates at, what oxygen concentration it delivers, and whether those parameters match the evidence for the application being targeted.

Considering the inspection and maintenance obligation. Hard-shell chambers are pressure vessels for human occupancy. They require periodic inspection against ASME PVHO-2 standards, and their maintenance history needs to be documented and verifiable. Teams that acquire hard-shell chambers and then fail to maintain them properly are creating a safety liability, not a clinical asset.

The Broader Pattern

The professional sports HBOT procurement landscape reflects a broader pattern in how the industry has developed. HBOT has become credible enough that major institutions want to be associated with it, but the regulatory and clinical complexity of operating it properly creates pressure toward the path of least resistance. Soft-shell chambers are that path.

The result is a situation where HBOT is simultaneously more visible in elite sport than it has ever been, and where the gap between what is being deployed and what the evidence supports is significant. Teams can point to their hyperbaric chambers as evidence of a sophisticated recovery programme. Whether those chambers are actually delivering the clinical benefit that the evidence supports is a different question.

For the athletes whose long-term neurological health depends on getting this right, that gap matters considerably more than it does for the teams' marketing materials.

The right chamber is not the most convenient chamber, or the cheapest chamber, or the one that requires the least regulatory engagement. It is the one that matches the clinical need, is operated correctly, and is maintained to the standard that a pressure vessel for human occupancy requires. In professional sport, that standard is not yet consistently being met.